Cerulean Shifts From Ovarian Cancer To Contraceptives In Reverse Merger With Daré
Executive Summary
Cerulean and privately-held Daré entered into a stock purchase agreement that will give the latter company's shareholders a majority stake in the combined company, which will focus on women's health – particularly contraceptives – instead of the former firm's nanoparticle-drug conjugates for cancer.
You may also be interested in...
Daré Bioscience On Prowl To Fill Gaps In Women's Sexual Health
Emerging Company Profile: The company applies its mid-stage in-licensing strategy to bring in novel products for female contraception and sexual arousal disorder.
Workforce Roundtable Part 3: Diversity And Progress – And Advice For Biopharma's Next Generation
Women in leadership roles has become a much discussed issue for the biopharma industry, but less attention seems to be focused on racial diversity. Scrip's panel talks about challenges and opportunities, and offers advice for next generation employees.
Workforce Roundtable Part 2: Creating A 'Sticky' Workplace, Boardroom Roles For Women, Millennials
Once you've created an attractive company culture for women and millennials, what else should be done to retain the next generation of biopharma leaders? For starters, Scrip's panelists say, give them opportunities to contribute – including in the boardroom - and be open to new ways of communication.